David M Dorfman

List of Publications by Year
in descending order

167 papers	8,758 citations	50276 46 h-index	45317 90 g-index
170 all docs	170 docs citations	170 times ranked	12203 citing authors

#	Article	IF	Citations
1	A case of peripheral Tâ€cell lymphoma, <scp>NOS</scp>, mimicking acute monocytic leukemia. American Journal of Hematology, 2022, 97, 1266-1267.	4.1	1
2	Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia, 2022, 36, 1088-1101.	7.2	6
3	Non-Hodgkin lymphoma mimicking acute leukemia: a report of six cases and review of the literature. Journal of Hematopathology, 2022, 15, 63-73.	0.4	3
4	<scp>AML</scp> with t(8;16) mimicking acute promyelocytic leukaemia. International Journal of Laboratory Hematology, 2022, 44, 997-998.	1.3	0
5	miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood, 2021, 137, 1905-1919.	1.4	8
6	Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection. Blood Advances, 2021, 5, 3690-3693.	5.2	9
7	Laboratory Workup of Lymphoma in Adults. American Journal of Clinical Pathology, 2021, 155, 12-37.	0.7	9
8	Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey. Archives of Pathology and Laboratory Medicine, 2021, 145, 336-342.	2.5	2
9	Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2021, 145, 269-290.	2.5	9
10	Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma. Blood, 2021, 138, 2688-2688.	1.4	0
11	Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients. Blood, 2021, 138, 504-504.	1.4	1
12	A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide. Haematologica, 2020, 105, e379-e381.	3.5	3
13	Impact of Sickle Cell Trait on Morbidity and Mortality from Sars-Cov-2 Infection. Blood, 2020, 136, 31-32.	1.4	0
14	Highly differentiated cytotoxic T cells in inclusion body myositis. Brain, 2019, 142, 2590-2604.	7.6	73
15	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961987603.	1.7	20
16	Utility of a Simple and Robust Flow Cytometry Assay for Rapid Clonality Testing in Mature Peripheral T-Cell Lymphomas. American Journal of Clinical Pathology, 2019, 151, 494-503.	0.7	31
17	Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas. American Journal of Surgical Pathology, 2019, 43, 102-109.	3.7	12
18	Pleomorphic mantle cell lymphoma mimicking diffuse large Bâ€cell lymphoma in peripheral blood and bone marrow. American Journal of Hematology, 2019, 94, 1170-1171.	4.1	0

#	Article	IF	Citations
19	Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine, 2019, 25, 776-783.	30.7	344
20	Use of a Blast Dominanceâ€“Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS). American Journal of Clinical Pathology, 2019, 151, 584-592.	0.7	2
21	Clonal Heterogeneity and Immune Tumor Microenvironment in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e318-e319.	0.4	0
22	High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e28-e29.	0.4	0
23	Acute myeloid leukemia with minimal differentiation (AML M0) mimicking acute lymphoblastic leukemia. American Journal of Hematology, 2019, 94, 955-956.	4.1	1
24	Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches. Blood, 2019, 134, 3079-3079.	1.4	0
25	High-Dimensional Heterogeneity of WaldenstrÃ¶m Macroglobulinemia within Its Immune Tumor Microenvironment. Blood, 2019, 134, 3975-3975.	1.4	1
26	Myeloma Heterogeneity within Its Complex Immune Ecosystem. Blood, 2019, 134, 4354-4354.	1.4	0
27	Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy. Blood, 2019, 134, 1804-1804.	1.4	0
28	Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling. Modern Pathology, 2018, 31, 553-561.	5.5	12
29	Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1289-1296.	2.3	10
30	Ectopic Intrathyroidal Thymic Tissue Mimicking Thyroid Nodules in Children. Journal of Ultrasound in Medicine, 2018, 37, 783-791.	1.7	28
31	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	12.8	80
32	Leukemic-phase progression of aleukemic mast cell leukemia. Blood, 2018, 131, 2406-2406.	1.4	1
33	Highly atypical myeloblasts in acute myeloid leukaemia with myelodysplasia-related changes in a patient with short telomere syndrome. British Journal of Haematology, 2018, 183, 536-536.	2.5	0
34	Circulating Myeloid-Derived Suppressor Cells Reflect Mycosis Fungoides/Sezary Syndrome Disease Stage and Response to Treatment. Blood, 2018, 132, 4127-4127.	1.4	1
35	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. Blood, 2018, 132, 3896-3896.	1.4	1
36	Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2017, 148, 33-41.	0.7	8

#	Article	IF	Citations
37	Myocardial Induction of Type 3 Deiodinase in Dilated Cardiomyopathy. Thyroid, 2017, 27, 732-737.	4.5	11
38	An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology. Leukemia and Lymphoma, 2017, 58, 2014-2016.	1.3	0
39	Flow Cytometry of TÂcells and T-cell Neoplasms. Clinics in Laboratory Medicine, 2017, 37, 725-751.	1.4	9
40	Mast Cell Disease Assessment by Flow Cytometric Analysis. Clinics in Laboratory Medicine, 2017, 37, 869-878.	1.4	2
41	Clinical Flow Cytometry: State-of-the-Art and New Approaches. Clinics in Laboratory Medicine, 2017, 37, xiii-xiv.	1.4	2
42	Realgar nanoparticles versus <scp>ATO</scp> arsenic compounds induce inÂvitro and inÂvivo activity against multiple myeloma. British Journal of Haematology, 2017, 179, 756-771.	2.5	26
43	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget, 2016, 7, 77326-77341.	1.8	45
44	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
45	FLOCK cluster analysis of plasma cell flow cytometry data predicts bone marrow involvement by plasma cell neoplasia. Leukemia Research, 2016, 48, 40-45.	0.8	8
46	Flow Cytometry of Nonhematopoietic Neoplasms. Acta Cytologica, 2016, 60, 336-343.	1.3	32
47	Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. Modern Pathology, 2016, 29, 1050-1057.	5.5	23
48	Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain, 2016, 139, 1348-1360.	7.6	93
49	Automated Nucleated RBC Measurement Using the Sysmex XE-5000 Hematology Analyzer. American Journal of Clinical Pathology, 2016, 145, 379-384.	0.7	11
50	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. Blood, 2016, 128, 3015-3015.	1.4	1
51	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1681-1681.	1.4	0
52	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. Blood, 2016, 128, 4483-4483.	1.4	0
53	EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood, 2015, 126, 1930-1939.	1.4	76
54	The Cyclophilin Aâ€“CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nature Medicine, 2015, 21, 572-580.	30.7	79

#	Article	IF	Citations
55	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4607-4618.	7.0	271
56	Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program. Archives of Pathology and Laboratory Medicine, 2015, 139, 1276-1280.	2.5	30
57	FLOCK Cluster Analysis of Mast Cell Event Clustering by High-Sensitivity Flow Cytometry Predicts Systemic Mastocytosis. American Journal of Clinical Pathology, 2015, 144, 764-770.	0.7	5
58	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	1.2	47
59	High-sensitivity flow cytometric analysis of mast cell clustering in systemic mastocytosis: a quantitative and statistical analysis. Leukemia and Lymphoma, 2015, 56, 1735-1741.	1.3	5
60	Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leukemia and Lymphoma, 2015, 56, 993-998.	1.3	3
61	Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leukemia and Lymphoma, 2015, 56, 2087-2091.	1.3	23
62	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. Blood, 2015, 126, 3252-3252.	1.4	2
63	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. Blood, 2015, 126, 502-502.	1.4	4
64	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. Blood, 2015, 126, 4001-4001.	1.4	0
65	Differential Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein in Low and High Grade B-Cell Non-Hodgkin Lymphomas and Differential Regulation of EZH2 Expression By p-ERK and MYC in High Grade B Cell Lymphomas. Blood, 2015, 126, 2660-2660.	1.4	0
66	Antigen expression patterns ofMYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry. Leukemia and Lymphoma, 2014, 55, 2592-2596.	1.3	13
67	Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2014, 370, 1327-1334.	27.0	52
68	Profile of CD103 Expression in T-cell Neoplasms. American Journal of Surgical Pathology, 2014, 38, 1557-1570.	3.7	16
69	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. American Journal of Surgical Pathology, 2014, 38, 768-775.	3.7	44
70	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood, 2014, 123, 1293-1296.	1.4	345
71	Mimicking Myeloma Niche Ex Vivo. Blood, 2014, 124, 2076-2076.	1.4	0
72	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	1.4	0

#	Article	IF	Citations
73	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	1.4	0
74	Radiotherapy in the management of localized primary cutaneous B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 726-730.	1.3	9
75	An Improved Algorithm for Activated Protein C Resistance and Factor V Leiden Screening. American Journal of Clinical Pathology, 2013, 140, 379-386.	0.7	9
76	CD200 Flow Cytometric Assessment and Semiquantitative Immunohistochemical Staining Distinguishes Hairy Cell Leukemia From Hairy Cell Leukemia-Variant and Other B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2013, 140, 536-543.	0.7	44
77	A Simplified Flow Cytometric Immunophenotyping Procedure for the Diagnosis of Effusions Caused by Epithelial Malignancies. American Journal of Clinical Pathology, 2013, 139, 672-681.	0.7	37
78	Sysmex XE-5000 Blast Q Flag Analysis. American Journal of Clinical Pathology, 2013, 140, 918-919.	0.7	3
79	Flow Cytometry Criteria for Systemic Mastocytosis: Bone Marrow Mast Cell Counts Do Not Always Count. American Journal of Clinical Pathology, 2013, 139, 406-407.	0.7	0
80	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS ONE, 2013, 8, e67306.	2.5	98
81	Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach. Blood, 2013, 122, 1378-1378.	1.4	0
82	Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Modern Pathology, 2012, 25, 1637-1643.	5.5	48
83	Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma. Leukemia and Lymphoma, 2012, 53, 1905-1910.	1.3	14
84	Bioinspired multivalent DNA network for capture and release of cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19626-19631.	7.1	266
85	High-Sensitivity Flow Cytometric Analysis for the Evaluation of Systemic Mastocytosis Including the Identification of a New Flow Cytometric Criterion for Bone Marrow Involvement. American Journal of Clinical Pathology, 2012, 138, 416-424.	0.7	16
86	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
87	CD200 (OX-2 Membrane Glycoprotein) is Expressed by Follicular T Helper Cells and in Angioimmunoblastic T-cell Lymphoma. American Journal of Surgical Pathology, 2011, 35, 76-83.	3.7	51
88	Single Tube, Six-Color Flow Cytometric Analysis Is a Sensitive and Cost-Effective Technique for Assaying Clonal Plasma Cells. American Journal of Clinical Pathology, 2010, 133, 694-699.	0.7	11
89	CD200 (OX-2 Membrane Glycoprotein) Expression in B Cellâ€“Derived Neoplasms. American Journal of Clinical Pathology, 2010, 134, 726-733.	0.7	65
90	The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms. Human Pathology, 2010, 41, 1486-1494.	2.0	28

#	Article	IF	Citations
91	Marrow-Infiltrating T Cells In Patients with Chronic Lymphocytic Leukemia Display Markers of Functional Impairment and Express PD-1. Blood, 2010, 116, 2417-2417.	1.4	0
92	Germinal-Center T-Helper-Cell Markers PD-1 and CXCL13 Are Both Expressed by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma. American Journal of Clinical Pathology, 2009, 131, 33-41.	0.7	92
93	Comparison of Russell Viper Venomâ€"Based and Activated Partial Thromboplastin Timeâ€"Based Screening Assays for Resistance to Activated Protein C. American Journal of Clinical Pathology, 2008, 130, 796-804.	0.7	10
94	A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions. Cancer Prevention Research, 2008, 1, 339-348.	1.5	24
95	Intraplacental Choriocarcinoma Arising in a Second Trimester Placenta With Partial Hydatidiform Mole. International Journal of Gynecological Pathology, 2008, PAP, 247-51.	1.4	19
96	Characteristic Expression Patterns of TCL1, CD38, and CD44 Identify Aggressive Lymphomas Harboring a MYC Translocation. American Journal of Surgical Pathology, 2008, 32, 113-122.	3.7	53
97	Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2827-2830.	7.1	122
98	TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells. Immunity, 2007, 27, 927-940.	14.3	536
99	Activated Protein C Resistance and Factor V Leiden: A Review. Archives of Pathology and Laboratory Medicine, 2007, 131, 866-871.	2.5	46
100	Carcinoma Showing Thymus-like Differentiation of the Thyroid (CASTLE): A Comparative Study. American Journal of Surgical Pathology, 2006, 30, 994-1001.	3.7	106
101	Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma. American Journal of Surgical Pathology, 2006, 30, 802-810.	3.7	331
102	Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. Journal of Clinical Investigation, 2006, 116, 414-421.	8.2	102
103	Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 2006, 12, 7174-7179.	7.0	133
104	Essential Role for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil Granulocytes. Molecular and Cellular Biology, 2006, 26, 8052-8060.	2.3	45
105	Interlaboratory Comparison of Immunohistochemical Testing for HER2: Results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. Archives of Pathology and Laboratory Medicine, 2006, 130, 1440-1445.	2.5	34
106	Concurrent Herpes Simplex Viral Lymphadenitis and Mantle Cell Lymphoma: A Case Report and Review of the Literature. Archives of Pathology and Laboratory Medicine, 2006, 130, 536-539.	2.5	10
107	The CD117 Immunohistochemistry Tissue Microarray Survey for Quality Assurance and Interlaboratory Comparison: A College of American Pathologists Cell Markers Committee Study. Archives of Pathology and Laboratory Medicine, 2006, 130, 779-782.	2.5	23
108	Discriminatory proteomic biomarker analysis identifies free hemoglobin in the cerebrospinal fluid of women with severe preeclampsia. American Journal of Obstetrics and Gynecology, 2005, 193, 957-964.	1.3	44

#	Article	IF	Citations
109	Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation. Vascular Medicine, 2005, 10, 23-27.	1.5	40
110	T-bet, a T cellâ€“associated transcription factor, is expressed in Hodgkin's lymphoma. Human Pathology, 2005, 36, 10-15.	2.0	31
111	CD5, CD10, and CD23 Expression in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 246-249.	2.1	71
112	The Host Resistance Locussst1Controls Innate Immunity toListeria monocytogenesInfection in Immunodeficient Mice. Journal of Immunology, 2004, 173, 5112-5120.	0.8	40
113	Identification of a novel gene, DZIP (DAZ-interacting protein), that encodes a protein that interacts with DAZ (deleted in azoospermia) and is expressed in embryonic stem cells and germ cells. Genomics, 2004, 83, 834-843.	2.9	58
114	T-bet, a T-Cell-Associated Transcription Factor, Is Expressed in a Subset of B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2004, 122, 292-297.	0.7	24
115	Automated Flow Cytometric Analysis of Blood Cells in Cerebrospinal Fluid: Analytic Performance. American Journal of Clinical Pathology, 2004, 121, 690-700.	0.7	18
116	Loss of Expression of the WNT/Î²-Catenin-Signaling Pathway Transcription Factors Lymphoid Enhancer Factor-1 (LEF-1) and T Cell Factor-1 (TCF-1) in a Subset of Peripheral T Cell Lymphomas. American Journal of Pathology, 2003, 162, 1539-1544.	3.8	55
117	Human Pumilio-2 is expressed in embryonic stem cells and germ cells and interacts with DAZ (Deleted) Tj ETQq1 1 0.784314 rgBT /Ov States of America, 2003, 100, 538-543.	7.1	211
118	CXCR4/CD184 Immunoreactivity in T-Cell Non-Hodgkin Lymphomas With an Overall Th1â€“ Th2+ Immunophenotype. American Journal of Clinical Pathology, 2003, 119, 424-430.	0.7	22
119	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. Journal of Immunology, 2003, 170, 1257-1266.	0.8	842
120	Differential Expression of T-bet, a T-box Transcription Factor Required for Th1 T-Cell Development, in Peripheral T-Cell Lymphomas. American Journal of Clinical Pathology, 2003, 120, 866-873.	0.7	28
121	Type 3 Iodothyronine Deiodinase Is Highly Expressed in the Human Uteroplacental Unit and in Fetal Epithelium. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1384-1388.	3.6	187
122	A profile of mycosis fungoides. Blood, 2003, 102, 778-778.	1.4	1
123	CD148 and CD27 are Expressed in B Cell Lymphomas Derived from both Memory and NaÃ¯ve B Cells. Leukemia and Lymphoma, 2002, 43, 1855-1858.	1.3	39
124	A 21-Year-Old Woman with Consumptive Hypothyroidism due to a Vascular Tumor Expressing Type 3 Iodothyronine Deiodinase. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4457-4461.	3.6	90
125	The Terminal Ileum Is Affected in Patients With Lymphocytic or Collagenous Colitis. American Journal of Surgical Pathology, 2002, 26, 1484-1492.	3.7	97
126	Normal d-dimer levels in emergency department patients suspected of acute pulmonary embolism. Journal of the American College of Cardiology, 2002, 40, 1475-1478.	2.8	127

#	Article	IF	Citations
127	Ploidy and imprinting in hydatidiform moles. Complementary use of flow cytometry and immunohistochemistry of the imprinted gene product p57KIP2 to assist molar classification. Journal of reproductive medicine, The, 2002, 47, 342-6.	0.2	25
128	Do nontriploid partial hydatidiform moles exist? A histologic and flow cytometric reevaluation of nontriploid specimens. Journal of reproductive medicine, The, 2002, 47, 363-8.	0.2	25
129	Phenotypic Characterization of Subsets of T Cell Lymphoma: Towards a Functional Classification of T Cell Lymphoma. Leukemia and Lymphoma, 2001, 40, 449-459.	1.3	20
130	The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis Fungoides. American Journal of Clinical Pathology, 2001, 115, 413-421.	0.7	80
131	Splendore-Hoeppli Phenomenon. Archives of Pathology and Laboratory Medicine, 2001, 125, 1515-1516.	2.5	35
132	Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: Increased sensitivity using flow cytometric analysis. Diagnostic Cytopathology, 2000, 23, 369-374.	1.0	83
133	The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood, 2000, 95, 627-632.	1.4	178
134	Recurrences in Nodal T-Cell Lymphoma. American Journal of Clinical Pathology, 2000, 114, 438-447.	0.7	12
135	Primary Marginal Zone Lymphoma of the Thymus. American Journal of Clinical Pathology, 2000, 113, 784-791.	0.7	50
136	Precursor B-cell Lymphoblastic Lymphoma. American Journal of Surgical Pathology, 2000, 24, 1480-1490.	3.7	203
137	DAZ Family Proteins Exist Throughout Male Germ Cell Development and Transit from Nucleus to Cytoplasm at Meiosis in Humans and Mice1. Biology of Reproduction, 2000, 63, 1490-1496.	2.7	173
138	Human DAZL1 Encodes a Candidate Fertility Factor in Women That Localizes to the Prenatal and Postnatal Germ Cells. Obstetrical and Gynecological Survey, 2000, 55, 154-155.	0.4	0
139	T Cells Mediate Treatment of Six-Day-Old Cytokine-Gene-Transfected Mouse Mammary Tumor. Pathobiology, 1999, 67, 3-11.	3.8	6
140	Hematogones as an Internal Control in Flow Cytometric Analysis of Suspected Acute Lymphoblastic Leukemia. Pediatric and Developmental Pathology, 1999, 2, 371-376.	1.0	5
141	Lymphoma Presenting as a Solitary Bone Lesion. American Journal of Clinical Pathology, 1999, 111, 171-178.	0.7	33
142	A Novel, Rapid, Multiparametric Approach for Flow Cytometric Analysis of Intranuclear Terminal Deoxynucleotidyl Transferase. American Journal of Clinical Pathology, 1999, 112, 343-348.	0.7	1
143	Treatment of Established Tumor Is Associated with ICAM-1 Upregulation and Reversed by CD8 Depletion in a Tumor Necrosis Factor-Alpha Gene Transfected Mouse Mammary Tumor. Pathobiology, 1999, 67, 186-195.	3.8	6
144	The Leukocyte Semaphorin CD100 Is Expressed in Most T-Cell, but Few B-Cell, Non-Hodgkin's Lymphomas. American Journal of Pathology, 1998, 153, 255-262.	3.8	33

#	Article	IF	Citations
145	Four-Color Flow Cytometric Immunophenotypic Determination of Peripheral Blood CD4⁺T-Lymphocyte Counts: A Comparison of Validity and Cost-Effectiveness With a Two-Color Method. American Journal of Clinical Pathology, 1998, 110, 465-470.	0.7	9
146	Murine Cytotoxic T Lymphocytes Recognize an Epitope in an EBNA-1 Fragment, but Fail to Lyse EBNA-1â€“expressing Mouse Cells. Journal of Experimental Medicine, 1998, 187, 445-450.	8.5	30
147	Characteristic Proliferations of Reticular and Dendritic Cells in Angioimmunoblastic Lymphoma. American Journal of Surgical Pathology, 1998, 22, 956-964.	3.7	66
148	Splenic Pathology in Myelodysplasia. American Journal of Surgical Pathology, 1998, 22, 1255-1266.	3.7	48
149	Absence of Dendritic Reticulum Cell Staining Is Helpful for Distinguishing T-Cell-Rich B-Cell Lymphoma From Lymphocyte Predominance Hodgkin's Disease. Applied Immunohistochemistry & Molecular Morphology, 1998, 6, 16-22.	2.0	10
150	T-Cell Blast Crisis in Chronic Myelogenous Leukemia:Immunophenotypic and Molecular Biologic Findings. American Journal of Clinical Pathology, 1997, 107, 168-176.	0.7	27
151	Leukemic Vasculitis:A Feature of Leukemia Cutis in Some Patients. American Journal of Clinical Pathology, 1997, 107, 637-642.	0.7	42
152	Impact of activated protein C resistance on general vascular surgical patients. Journal of Vascular Surgery, 1997, 25, 1054-1060.	1.1	24
153	Non-Hodgkin's lymphomas: current classification and management. Ca-A Cancer Journal for Clinicians, 1997, 47, 351-372.	329.8	48
154	MR imaging of dedifferentiated chondrosarcoma. Clinical Imaging, 1997, 21, 170-174.	1.5	9
155	Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity. American Journal of Surgical Pathology, 1997, 21, 936-940.	3.7	147
156	Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden. American Heart Journal, 1996, 131, 1145-1148.	2.7	100
157	The Utility of Flow Cytometric Immunophenotypic Analysis in the Distinction of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia From Mantle Cell Lymphoma. American Journal of Clinical Pathology, 1996, 105, 451-457.	0.7	72
158	Ewing's sarcoma of the sacrum. Skeletal Radiology, 1996, 25, 302-304.	2.0	9
159	Skeletal muscle lymphoma: observations at MR imaging. Skeletal Radiology, 1996, 25, 425-430.	2.0	37
160	Solitary Fibrous Tumor of the Orbit. American Journal of Surgical Pathology, 1994, 18, 281-287.	3.7	259
161	Kikuchi-Fujimoto Disease of the Neck Update. Annals of Otology, Rhinology and Laryngology, 1993, 102, 11-15.	1.1	49
162	[23] Amplification of bacteriophage library inserts using polymerase chain reaction. Methods in Enzymology, 1993, 218, 336-340.	1.0	0

#	Article	IF	Citations
163	The 5.8S ribosomal RNA gene ofTrypannsoma brucei: structural and transciiptional studies. Nucleic Acids Research, 1985, 13, 3533-3549.	14.5	26
164	Characterization of the Trypanosoma brucei 5S ribosomal RNA gene and transcript: the 5S rRNA is a spliced-leader-independent species. Gene, 1985, 35, 131-141.	2.2	57
165	Characterization of the 1.35 Kilobase DNA repeat unit containing the conserved 35 nucleotides at the 5â€²-termini of variable surface glyeoprotein mRNAs InTrypanosoma brucei. Nucleic Acids Research, 1984, 12, 4907-4920.	14.5	61
166	DNA Rearrangements of the Variable Surface Antigen Genes of the Trypanosomes1. Journal of Protozoology, 1984, 31, 65-73.	0.8	30
167	The ILtat 1.4 surface antigen gene family ofTrypanosma brucei. Nucleic Acids Research, 1982, 10, 6581-6595.	14.5	33